title: Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.
abstract: BACKGROUND
  Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging.
  
  
  METHODS
  We conducted a literature search using the PubMed database in order to assess the efficacy and safety profile of brodalumab. The search included the following key words: "psoriasis" and "IL-17" or "brodalumab." We also reviewed citations within articles to identify relevant sources.
  
  
  RESULTS
  At week 12, the proportion of patients attaining a 75% improvement from the baseline Psoriasis Area and Severity Index (PASI 75) was similar among the three phase III trials (AMAGINE-1, 83%; AMAGINE-2, 86%; AMAGINE-3, 85%). Brodalumab remained efficacious through 52 weeks of treatment. It maintained a satisfactory safety profile; the most frequently reported adverse events consisted of nasopharyngitis, headache, upper respiratory tract infection, and arthralgia.
  
  
  CONCLUSIONS
  Use of brodalumab revealed prompt clinical improvement and a favorable short-term safety profile in phase III trials, although further extension studies are needed to assess long-term safety. Based on the results, brodalumab appears to be a potent therapeutic option for patients with moderate-to-severe plaque-type psoriasis.
authors.affiliation: University of Vermont College of Medicine, Burlington, VT, USA. Benjamin.farahnik@ucsf.edu.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Farahnik
authors.affiliation: David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
authors.forename: Kourosh
authors.initials: K
authors.lastname: Beroukhim
authors.affiliation: School of Medicine, University of California, Irvine, Irvine, CA, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Abrouk
authors.affiliation: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: Mio
authors.initials: M
authors.lastname: Nakamura
authors.affiliation: University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
authors.forename: Tian Hao
authors.initials: TH
authors.lastname: Zhu
authors.affiliation: David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
authors.forename: Rasnik
authors.initials: R
authors.lastname: Singh
authors.affiliation: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: Kristina
authors.initials: K
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: Tina
authors.initials: T
authors.lastname: Bhutani
authors.affiliation: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Koo
keywords: AMAGINE; Anti-interleukin-17; Biologics; Brodalumab; Interleukin 17; Phase III; Psoriasis